Loading clinical trials...
Loading clinical trials...
Smokers with serious mental illness including those with schizophrenia and bipolar disorder infrequently attempt and attain sustained smoking abstinence and have a 25-year shorter lifespan due to smoking-related illness. This study will examine whether reducing the nicotine content of cigarettes to non-addicting levels is a viable method of reducing smoking in smokers with serious mental illness. Smokers will be randomized to one of two experimental conditions: 1) very low nicotine content (VLNC) cigarettes or 2) normal nicotine content (NNC) cigarettes. Participants will be assessed for patterns of tobacco use, biomarkers of exposure, subjective responses (e.g., satisfaction, craving, withdrawal symptoms), psychiatric symptoms, cognitive performance, smoking cue reactivity and smoking topography.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Brown University
Providence, Rhode Island, United States
Start Date
November 17, 2014
Primary Completion Date
August 31, 2017
Completion Date
August 31, 2017
Last Updated
April 9, 2018
58
ACTUAL participants
Very low nicotine content cigarettes
OTHER
standard nicotine content cigarettes
OTHER
Lead Sponsor
Brown University
Collaborators
NCT06543407
NCT06488443
NCT06218056
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions